Tocilizumab in Combination with Standard of Care in Patients with Severe COVID-19 Pneumonia: Efficacy and Safety from a Phase 3 Clinical Trial in Japan
JOURNAL OF INFECTION AND CHEMOTHERAPY(2025)
Key words
Biomarkers,Clinical trial,COVID-19 pneumonia,Interleukin-6,Severe acute respiratory syndrome coronavirus 2,Tocilizumab
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined